Two Stages, One Genre: What "Paranormal Activity" on Broadway and "Obsession" at the Box Office Say About Horror Right Now
Horror rarely gets credit for range. The genre is often treated, in industry conversation, as a single product: cheap to make, reliably profitable, easy to dismiss. Two very different successes this year complicate that picture. Obsession, a $750,000 independent film, has become the highest-grossing horror release of 2026 and one of the most profitable films in recent memory. Paranormal Activity, the found-footage franchise that helped define low-budget horror in 2007, has been reborn as a stage play that is currently selling out the August Wilson Theatre on Broadway. Neither is a fluke, and neither is really a separate story. Read together, they say something specific about where horror is headed as a business and as a medium — and, for the studios, producers, and rights holders that work with our Firm, they suggest where the next round of deal-making is likely to happen.
The economics haven't changed. The confidence has.
Obsession was directed, written, and edited by Curry Barker on a budget of $750,000, produced under Blumhouse Productions alongside Capstone Studios and Tea Shop Productions. After premiering at the Toronto International Film Festival in September 2025, it opened wide through Focus Features in May 2026 and has since reportedly grossed roughly $510 million worldwide — making it, by most industry counts, the fifth-highest-grossing horror film ever made and the tenth-highest-grossing film of any genre released in 2026. A 93% Rotten Tomatoes score, an A- CinemaScore, and reviews praising the cast's emotional commitment suggest the film earned its audience rather than simply riding a marketing wave.
That ratio of budget to gross is not new for horror. Analysts at The Numbers have found that nearly half of the twenty most profitable films made since 1977 are horror titles, and Blumhouse's own catalog — nearly $6 billion in lifetime global box office across 24 years, according to Sherwood News — is built almost entirely on the same logic that produced Obsession: small budgets, character-driven scripts, and a willingness to let genuine craft substitute for spectacle.
What has changed is how deliberately studios are now pursuing that model rather than treating it as a lucky outlier. Jason Blum has been explicit about the underlying thesis: horror requires "authenticity" in performance and writing to work at all, because audiences have to forget they are watching a movie to be frightened by it (Sherwood News). That is a creative argument as much as a financial one, and it is the reason the genre keeps outperforming its budgets when the material is taken seriously.
The theatrical experiment: horror as an event, not just a release
The Broadway production of Paranormal Activity is a different kind of bet, and arguably a more interesting one. Written by Levi Holloway and based on the film franchise, the play originated at Leeds Playhouse in July 2024, transferred to the West End in December 2025, and opened on Broadway on August 25, 2026, with Blumhouse joining as a Broadway producer alongside the original creative team. It is directed by Felix Barrett — best known for immersive, environment-driven work like Sleep No More — with illusion design by Chris Fisher, and it has been reviewed not as a gimmick but as a piece of craft: the Los Angeles Times called it "truly scary" and potentially the best-staged production of the year, and The Guardian noted that the production treats horror as "an art form" rather than relying on jump scares.
The commercial numbers back up the critical reaction. As of the week ending September 6, 2026, the production had grossed $2.68 million total, with a single-week high of $790,990.80, an average ticket price of $82.44, and average capacity of about 99% — a near-total sellout (Playbill). It has also picked up a 2026 Olivier Award nomination for Best Entertainment or Comedy Play. For a genre with no prior track record of sustained commercial success on Broadway, that is a meaningful signal: audiences will pay premium theater prices for horror when the format genuinely can't be replicated at home.
That last point is the connective tissue between these two successes, and it is the one Blum has made most directly. He has argued publicly that horror underperforms on streaming precisely because it is too easy to disengage from at home — pause the film, turn on a light, put down the phone — and that the genre's real competitive advantage is the theatrical experience itself, whether that theater is a multiplex or a Broadway house (Variety). Obsession succeeded in part because a mass audience chose to see it in a cinema rather than wait for streaming. Paranormal Activity succeeded by making the live, unrepeatable nature of a performance the entire premise of the ticket.
What this suggests about the genre — and about where the world is moving
Three things seem worth drawing out of this moment, with the caveat that each is a read on a still-developing trend rather than a settled conclusion.
First, horror's economics reward IP that can travel across mediums rather than IP that is exhausted by a single format. Paranormal Activity is nearly two decades old as a screen property; its value did not run out when the found-footage cycle did. The same underlying premise — an unseen entity terrorizing a domestic space — was portable enough to become an entirely new stage work with its own creative team, its own story, and its own audience. That portability is itself a licensable and structurable asset, and studios sitting on dormant horror franchises may increasingly look at stage, immersive, and experiential formats as a second life for material that would otherwise sit unused.
Second, the low-budget, high-craft model that built Blumhouse's film business appears to be exportable to formats beyond film — theater chief among them. That has implications for how these projects are financed and structured, since a play built around illusion design, sound engineering, and controlled scares carries a different cost, insurance, and risk profile than either a conventional film budget or a conventional Broadway musical. Producers and investors approaching this kind of cross-format horror project should expect financing, insurance, and rights structures that don't map neatly onto either industry's standard templates — a point worth raising with counsel early, rather than after deal terms are set.
Third, both successes reinforce that horror's audience is not shrinking in the streaming era — it may simply be relocating toward experiences streaming cannot replicate. Whether that pattern holds for the next franchise adaptation, or whether Paranormal Activity and Obsession prove to be well-executed exceptions rather than a durable trend, is not yet something the data can answer with confidence. The two data points here are strong, but they are two data points, drawn from a single studio's slate, in a single calendar year.
What is clear is that the genre's reputation for being formulaic has always undersold its actual behavior at the box office and, now, at the box office of a different kind. For clients holding horror IP, evaluating a cross-media adaptation, or structuring financing around a low-budget genre project, the practical questions — how rights are licensed across film and stage, how to create long-term, franchise value, how to preserve and create value in the underlying property across multiple verticals — are the kind that benefit from being addressed at the term-sheet stage rather than after a deal is announced.
